Literature DB >> 29325444

Redox Paradox: A Novel Approach to Therapeutics-Resistant Cancer.

Luksana Chaiswing1, William H St Clair2, Daret K St Clair1.   

Abstract

SIGNIFICANCE: Cancer cells that are resistant to radiation and chemotherapy are a major problem limiting the success of cancer therapy. Aggressive cancer cells depend on elevated intracellular levels of reactive oxygen species (ROS) to proliferate, self-renew, and metastasize. As a result, these aggressive cancers maintain high basal levels of ROS compared with normal cells. The prominence of the redox state in cancer cells led us to consider whether increasing the redox state to the condition of oxidative stress could be used as a successful adjuvant therapy for aggressive cancers. Recent Advances: Past attempts using antioxidant compounds to inhibit ROS levels in cancers as redox-based therapy have met with very limited success. However, recent clinical trials using pro-oxidant compounds reveal noteworthy results, which could have a significant impact on the development of strategies for redox-based therapies. CRITICAL ISSUES: The major objective of this review is to discuss the role of the redox state in aggressive cancers and how to utilize the shift in redox state to improve cancer therapy. We also discuss the paradox of redox state parameters; that is, hydrogen peroxide (H2O2) as the driver molecule for cancer progression as well as a target for cancer treatment. FUTURE DIRECTIONS: Based on the biological significance of the redox state, we postulate that this system could potentially be used to create a new avenue for targeted therapy, including the potential to incorporate personalized redox therapy for cancer treatment.

Entities:  

Keywords:  H2O2; personalized redox therapy; redox state; resistant cancer; rewired redox state

Mesh:

Substances:

Year:  2018        PMID: 29325444      PMCID: PMC6157438          DOI: 10.1089/ars.2017.7485

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  387 in total

1.  Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells.

Authors:  J M Grad; N J Bahlis; I Reis; M M Oshiro; W S Dalton; L H Boise
Journal:  Blood       Date:  2001-08-01       Impact factor: 22.113

2.  Effect of cytochrome c on the generation and elimination of O2*- and H2O2 in mitochondria.

Authors:  Yungang Zhao; Zhi-Bo Wang; Jian-Xing Xu
Journal:  J Biol Chem       Date:  2002-11-14       Impact factor: 5.157

3.  NADPH oxidase 1 plays a critical mediating role in oncogenic Ras-induced vascular endothelial growth factor expression.

Authors:  D Komatsu; M Kato; J Nakayama; S Miyagawa; T Kamata
Journal:  Oncogene       Date:  2008-05-05       Impact factor: 9.867

4.  A recombinant MnSOD is radioprotective for normal cells and radiosensitizing for tumor cells.

Authors:  Antonella Borrelli; Antonella Schiattarella; Roberto Mancini; Brunello Morrica; Vincenzo Cerciello; Maria Mormile; Valentina d'Alesio; Laura Bottalico; Francesco Morelli; Maria D'Armiento; Francesco Paolo D'Armiento; Aldo Mancini
Journal:  Free Radic Biol Med       Date:  2008-10-25       Impact factor: 7.376

Review 5.  NADPH oxidase-dependent signaling in endothelial cells: role in physiology and pathophysiology.

Authors:  Randall S Frey; Masuko Ushio-Fukai; Asrar B Malik
Journal:  Antioxid Redox Signal       Date:  2009-04       Impact factor: 8.401

6.  Mitochondrial ROS and radiation induced transformation in mouse embryonic fibroblasts.

Authors:  Changbin Du; Zhen Gao; Venkatasubbaiah A Venkatesha; Amanda L Kalen; Leena Chaudhuri; Douglas R Spitz; Joseph J Cullen; Larry W Oberley; Prabhat C Goswami
Journal:  Cancer Biol Ther       Date:  2009-10-29       Impact factor: 4.742

7.  Expression of manganese superoxide dismutase reduces tumor control radiation dose: gene-radiotherapy.

Authors:  M Urano; M Kuroda; R Reynolds; T D Oberley; D K St Clair
Journal:  Cancer Res       Date:  1995-06-15       Impact factor: 12.701

Review 8.  An educational overview of the chemistry, biochemistry and therapeutic aspects of Mn porphyrins--From superoxide dismutation to H2O2-driven pathways.

Authors:  Ines Batinic-Haberle; Artak Tovmasyan; Ivan Spasojevic
Journal:  Redox Biol       Date:  2015-02-07       Impact factor: 11.799

Review 9.  Hydrogen peroxide as a central redox signaling molecule in physiological oxidative stress: Oxidative eustress.

Authors:  Helmut Sies
Journal:  Redox Biol       Date:  2017-01-05       Impact factor: 11.799

10.  CNS bioavailability and radiation protection of normal hippocampal neurogenesis by a lipophilic Mn porphyrin-based superoxide dismutase mimic, MnTnBuOE-2-PyP5.

Authors:  David Leu; Ivan Spasojevic; Huy Nguyen; Brian Deng; Artak Tovmasyan; Tin Weitner; Romulo S Sampaio; Ines Batinic-Haberle; Ting-Ting Huang
Journal:  Redox Biol       Date:  2017-04-22       Impact factor: 11.799

View more
  26 in total

Review 1.  Plausible biochemical mechanisms of chemotherapy-induced cognitive impairment ("chemobrain"), a condition that significantly impairs the quality of life of many cancer survivors.

Authors:  Xiaojia Ren; Diana Boriero; Luksana Chaiswing; Subbarao Bondada; Daret K St Clair; D Allan Butterfield
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-02-10       Impact factor: 5.187

Review 2.  The emergence of nanoporous materials in lung cancer therapy.

Authors:  Deepika Radhakrishnan; Shan Mohanan; Goeun Choi; Jin-Ho Choy; Steffi Tiburcius; Hoang Trung Trinh; Shankar Bolan; Nikki Verrills; Pradeep Tanwar; Ajay Karakoti; Ajayan Vinu
Journal:  Sci Technol Adv Mater       Date:  2022-07-20       Impact factor: 7.821

Review 3.  Extracellular Vesicles and Cancer Therapy: Insights into the Role of Oxidative Stress.

Authors:  Jenni Ho; Luksana Chaiswing; Daret K St Clair
Journal:  Antioxidants (Basel)       Date:  2022-06-17

4.  The RelB-BLNK Axis Determines Cellular Response to a Novel Redox-Active Agent Betamethasone during Radiation Therapy in Prostate Cancer.

Authors:  Luksana Chaiswing; Fangfang Xu; Yanming Zhao; Jon Thorson; Chi Wang; Daheng He; Jinpeng Lu; Sally R Ellingson; Weixiong Zhong; Kristy Meyer; Wei Luo; William St Clair; Daret St Clair
Journal:  Int J Mol Sci       Date:  2022-06-08       Impact factor: 6.208

Review 5.  Antioxidant Therapy in Cancer: Rationale and Progress.

Authors:  Maochao Luo; Li Zhou; Zhao Huang; Bowen Li; Edouard C Nice; Jia Xu; Canhua Huang
Journal:  Antioxidants (Basel)       Date:  2022-06-08

6.  NUPR1 contributes to radiation resistance by maintaining ROS homeostasis via AhR/CYP signal axis in hepatocellular carcinoma.

Authors:  Yizhi Zhan; Zhanqiao Zhang; Yuechen Liu; Yuan Fang; Yuwen Xie; Yilin Zheng; Guoxin Li; Li Liang; Yi Ding
Journal:  BMC Med       Date:  2022-10-19       Impact factor: 11.150

7.  Radiation-Mediated Tumor Growth Inhibition Is Significantly Enhanced with Redox-Active Compounds That Cycle with Ascorbate.

Authors:  Artak Tovmasyan; Jacqueline C Bueno-Janice; Melba C Jaramillo; Romulo S Sampaio; Julio S Reboucas; Natalia Kyui; Ludmil Benov; Brian Deng; Ting-Ting Huang; Margaret E Tome; Ivan Spasojevic; Ines Batinic-Haberle
Journal:  Antioxid Redox Signal       Date:  2018-03-27       Impact factor: 8.401

8.  Enhanced in vitro anticancer activity of yeast expressed recombinant glucose oxidase versus commercial enzyme.

Authors:  Evelyn Martínez-Mora; María Del Rosario González-González; Xristo Zarate; Pilar Carranza-Rosales; Mónica A Ramírez-Cabrera; Isaías Balderas-Rentería; Eder Arredondo-Espinoza
Journal:  Appl Microbiol Biotechnol       Date:  2021-02-22       Impact factor: 4.813

9.  Reactive oxygen species (ROS) generation as an underlying mechanism of inorganic phosphate (Pi)-induced mineralization of osteogenic cells.

Authors:  Sana Khalid; Hajime Yamazaki; Mairobys Socorro; Daisy Monier; Elia Beniash; Dobrawa Napierala
Journal:  Free Radic Biol Med       Date:  2020-04-21       Impact factor: 7.376

Review 10.  Reactive oxygen species (ROS) as pleiotropic physiological signalling agents.

Authors:  Helmut Sies; Dean P Jones
Journal:  Nat Rev Mol Cell Biol       Date:  2020-03-30       Impact factor: 113.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.